702 related articles for article (PubMed ID: 32798146)
41. Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study.
Takahashi K; Urabe F; Suhara Y; Nakano J; Yoshihara K; Goto Y; Sadakane I; Koike Y; Yata Y; Suzuki H; Kurawaki S; Miyajima K; Iwatani K; Imai Y; Sakanaka K; Nakazono M; Kurauchi T; Kayano S; Onuma H; Aikawa K; Yanagisawa T; Tashiro K; Tsuzuki S; Koike Y; Furuta A; Miki J; Kimura T
Jpn J Clin Oncol; 2023 Dec; 53(12):1208-1214. PubMed ID: 37647644
[TBL] [Abstract][Full Text] [Related]
42. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy.
Rodrigues Pessoa R; Morrison JC; Konety B; Gershman B; Maroni P; Kukreja JB; Cost N; Flaig T; Kessler E; Sharma P; Kim SP
Urol Oncol; 2021 Dec; 39(12):832.e9-832.e15. PubMed ID: 33820697
[TBL] [Abstract][Full Text] [Related]
43. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy.
Lee KS; Kim KH; Yoon YE; Choi KH; Yang SC; Han WK
Korean J Urol; 2015 Jan; 56(1):41-7. PubMed ID: 25598935
[TBL] [Abstract][Full Text] [Related]
44. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
[TBL] [Abstract][Full Text] [Related]
45. Histological variants and lymphovascular invasion in upper tract urothelial carcinoma can stratify prognosis after radical nephroureterectomy.
Takemoto K; Hayashi T; Hsi RS; Kobatake K; Sekino Y; Kitano H; Ikeda K; Goto K; Hieda K; Sentani K; Kajiwara M; Nishizaka T; Teishima J; Oue N; Hinata N
Urol Oncol; 2022 Dec; 40(12):539.e9-539.e16. PubMed ID: 36244916
[TBL] [Abstract][Full Text] [Related]
46. Chemotherapy increases survival and downstaging of upper tract urothelial cancer.
Davaro F; May A; McFerrin C; Raza SJ; Siddiqui S; Hamilton Z
Can J Urol; 2019 Oct; 26(5):9938-9944. PubMed ID: 31629443
[TBL] [Abstract][Full Text] [Related]
47. Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
Narita C; Urabe F; Fukuokaya W; Iwatani K; Imai Y; Yasue K; Mori K; Aikawa K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Yamada Y; Yuen SKK; Teoh JY; Shimomura T; Yamada H; Furuta A; Miki J; Kimura T;
Clin Genitourin Cancer; 2024 Jun; 22(3):102082. PubMed ID: 38641443
[TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology: A Systematic Review and Meta-Analysis of Survival Outcomes and Pathological Features.
Kim DK; Kim JH; Park JY; Gwon YN; Kim KM; Yang WJ; Doo SW; Song YS
Clin Genitourin Cancer; 2024 Feb; 22(1):e53-e65.e1. PubMed ID: 37598012
[TBL] [Abstract][Full Text] [Related]
49. The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis.
Stangl-Kremser J; Muto G; Grosso AA; Briganti A; Comperat E; Di Maida F; Montironi R; Remzi M; Pradere B; Soria F; Albisinni S; Roupret M; Shariat SF; Minervini A; Teoh JY; Moschini M; Cimadamore A; Mari A;
Urol Oncol; 2022 Jun; 40(6):243-261. PubMed ID: 35241364
[TBL] [Abstract][Full Text] [Related]
50. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
[TBL] [Abstract][Full Text] [Related]
51. Lymphovascular invasion as a prognostic factor in the upper urinary tract urothelial carcinoma: a systematic review and meta-analysis.
Ku JH; Byun SS; Jeong H; Kwak C; Kim HH; Lee SE
Eur J Cancer; 2013 Aug; 49(12):2665-80. PubMed ID: 23721778
[TBL] [Abstract][Full Text] [Related]
52. Impact of histologic variants on the oncological outcomes of patients with upper urinary tract cancers treated with radical surgery: a multi-institutional retrospective study.
Murakami Y; Matsumoto K; Ikeda M; Hirayama T; Utsunomiya T; Koguchi D; Matsuda D; Okuno N; Taoka Y; Irie A; Iwamura M
Int J Clin Oncol; 2019 Nov; 24(11):1412-1418. PubMed ID: 31197556
[TBL] [Abstract][Full Text] [Related]
53. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
[TBL] [Abstract][Full Text] [Related]
54. Comparison of Adjuvant Chemotherapy for Upper Tract versus Lower Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Jazayeri SB; Liu JS; Weissman B; Lester J; Samadi DB; Feuerstein MA
Curr Urol; 2019 Jul; 12(4):177-187. PubMed ID: 31602183
[TBL] [Abstract][Full Text] [Related]
55. Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study.
Kagawa H; Urabe F; Kiuchi Y; Katsumi K; Yamaguchi R; Suhara Y; Yoshihara K; Goto Y; Sadakane I; Yata Y; Saito S; Kurawaki S; Ajisaka S; Miyajima K; Takahashi K; Iwatani K; Imai Y; Sakanaka K; Nakazono M; Kurauchi T; Kayano S; Onuma H; Aikawa K; Yanagisawa T; Tashiro K; Tsuzuki S; Furuta A; Miki J; Kimura T;
Int J Clin Oncol; 2024 Jan; 29(1):55-63. PubMed ID: 37863996
[TBL] [Abstract][Full Text] [Related]
56. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis.
Guo RQ; Hong P; Xiong GY; Zhang L; Fang D; Li XS; Zhang K; Zhou LQ
BJU Int; 2018 Feb; 121(2):184-193. PubMed ID: 29032580
[TBL] [Abstract][Full Text] [Related]
57. Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study.
Kang HW; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YD; Ha YS; Kim TH; Kwon TG; Byun SS; Jeh SU; Kim WJ
J Korean Med Sci; 2017 Feb; 32(2):335-342. PubMed ID: 28049247
[TBL] [Abstract][Full Text] [Related]
58. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
Tabayoyong W; Li R; Gao J; Kamat A
Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
[TBL] [Abstract][Full Text] [Related]
59. Oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: an updated meta-analysis.
Piszczek R; Nowak Ł; Krajewski W; Chorbińska J; Poletajew S; Moschini M; Kaliszewski K; Zdrojowy R
World J Surg Oncol; 2021 Apr; 19(1):129. PubMed ID: 33882936
[TBL] [Abstract][Full Text] [Related]
60. Perioperative chemotherapy for upper tract urothelial cancer.
Alva AS; Matin SF; Lerner SP; Siefker-Radtke AO
Nat Rev Urol; 2012 Apr; 9(5):266-73. PubMed ID: 22487872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
